CAPVAXIVE Merck Sharp & Dohme (Australia) Pty Ltd
Product name
CAPVAXIVE
Accepted date
Dec-2025
Active ingredients
Pneumococcal purified capsular polysaccharides
Proposed indication
CAPVAXIVE is a vaccine that that is proposed to protect against pneumococcal disease, which is caused by the bacteria Streptococcus pneumoniae. It protects against the specific serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B.
It is approved for use in:
•adults aged 18 years and older
•children and teenagers aged 2 to under 18 years who have a higher risk of pneumococcal disease
CAPVAXIVE does not protect against pneumococcal strains that are not included in this list.
It is approved for use in:
•adults aged 18 years and older
•children and teenagers aged 2 to under 18 years who have a higher risk of pneumococcal disease
CAPVAXIVE does not protect against pneumococcal strains that are not included in this list.
Application type
C (new indication)
Publication date
Dec-2025